Tata Capital Growth Fund plans to acquire _______% stake in Biocon Biologics India for 30 Million USD
Answer with explanationAnswer: Option D
Biocon Biologics India approved the primary equity investment of around Rs.225 crores (30 Million USD) by Tata Capital Growth Fund for a 0.85% minority stake in Biocon Biologics, biosimilar business, at an equity valuation of around Rs. 26,250 crores (3.5 billion USD) and enterprise valuation of around Rs. 30,400 crores (4 billion USD).